Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has received a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $31.6667.

A number of research analysts have recently weighed in on the company. TD Cowen assumed coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a “buy” rating on the stock. Cowen assumed coverage on Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating on the stock. HC Wainwright upped their target price on Avalo Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Cantor Fitzgerald assumed coverage on Avalo Therapeutics in a research note on Friday, August 15th. They issued an “overweight” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Tuesday, October 14th.

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $16.09 on Wednesday. The stock’s 50-day simple moving average is $13.24 and its 200-day simple moving average is $8.32. The firm has a market capitalization of $211.62 million, a PE ratio of -0.89 and a beta of 0.94. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $19.41.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.49). Sell-side analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently modified their holdings of AVTX. Quadrature Capital Ltd purchased a new stake in shares of Avalo Therapeutics in the second quarter worth about $55,000. Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics during the second quarter worth approximately $56,000. ADAR1 Capital Management LLC purchased a new position in Avalo Therapeutics during the first quarter worth approximately $80,000. Geode Capital Management LLC boosted its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares in the last quarter. Finally, Velan Capital Investment Management LP boosted its position in Avalo Therapeutics by 38.4% during the second quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after purchasing an additional 43,000 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.